Labcorp Holdings Inc. (LH)

Market Cap	21.42B
Revenue (ttm)	13.77B
Net Income (ttm)	855.20M
Shares Out	82.90M
EPS (ttm)	10.19
PE Ratio	25.37
Forward PE	15.03
Dividend	$2.88 (1.11%)
Ex-Dividend Date	Nov 26, 2025

Volume	679,324
Open	261.45
Previous Close	261.48
Day's Range	257.55 - 261.65
52-Week Range	209.38 - 293.72
Beta	0.96
Analysts	Strong Buy
Price Target	299.00 (+15.72%)
Earnings Date	Oct 28, 2025

About LH

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1971
• Employees: 70,000
• Stock Exchange: NYSE
• Ticker Symbol: LH
• Website: https://www.labcorp.com

Financial Performance

In 2024, Labcorp Holdings's revenue was $13.01 billion, an increase of 6.97% compared to the previous year's $12.16 billion. Earnings were $746.00 million, an increase of 78.47%.

Analyst Forecast

According to 13 analysts, the average rating for LH stock is "Strong Buy." The 12-month stock price target is $299.0, which is an increase of 15.72% from the latest price.

Price Target

$299.0

(15.72% upside)

Analyst Consensus: Strong Buy